Prescription drug · ANDA
Dexamethasone NDC 66993-730
Dexamethasone 4 mg/1 · Tablet · Oral · Prasco Laboratories
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 66993-730-02 | 66993073002 | 100 TABLET in 1 BOTTLE (66993-730-02)Marketed from Apr 30, 2022 | |
| 66993-730-80 | 66993073080 | 10 BLISTER PACK in 1 CARTON (66993-730-80) / 10 TABLET in 1 BLISTER PACK (66993-730-51)Marketed from Apr 3, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Dexamethasone
- Generic name (nonproprietary)
- dexamethasone
- Active ingredients
- Dexamethasone — 4 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Prasco Laboratories
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 080399
- Marketing start
- Listing expires
- Other FDA classes
- Corticosteroid Hormone Receptor Agonists (Mechanism)
- Identifiers
- Product ID 66993-730_64545c32-2309-4fa4-9d9e-bfecf16244b0SPL ID 64545c32-2309-4fa4-9d9e-bfecf16244b0SPL set ID bfce6b49-f7ff-4ec7-9580-b730f0a207d7RxCUI 197582UNII 7S5I7G3JQLUPC 0366993730028
- Pharmacologic class
- Corticosteroid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N466993073002followed by a unit qualifier and the quantityPackage 66993-0730-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocortico…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 080399
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Dexamethasone | Dexamethasone 4 mg/1 | TabletOral | A-S Medication Solutions | 50090-6151 |
| Dexamethasone | Dexamethasone 4 mg/1 | TabletOral | A-S Medication Solutions | 50090-6152 |